44 related articles for article (PubMed ID: 38643078)
1. Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer.
Wang DQ; Xu WH; Cheng XW; Hua L; Ge XS; Liu L; Gao X
Front Immunol; 2024; 15():1407632. PubMed ID: 38840913
[TBL] [Abstract][Full Text] [Related]
2. Personalized prediction of postoperative complication and survival among Colorectal Liver Metastases Patients Receiving Simultaneous Resection using machine learning approaches: A multi-center study.
Chen Q; Chen J; Deng Y; Bi X; Zhao J; Zhou J; Huang Z; Cai J; Xing B; Li Y; Li K; Zhao H
Cancer Lett; 2024 May; 593():216967. PubMed ID: 38768679
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
4. Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer.
Choi Y; Lee J; Shin K; Lee JW; Kim JW; Lee S; Choi YJ; Park KH; Kim JH
BMC Cancer; 2024 Apr; 24(1):502. PubMed ID: 38643078
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of Chemotherapy with Trastuzumab in Advanced Gastric Cancer].
Kawada J; Nakatsuka R; Motoori M; Miyazaki S; Danno K; Kubota M; Matsuda C; Nishikawa K; Fujitani K; Iwase K; Tsujinaka T; Tanaka Y
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2091-3. PubMed ID: 26805274
[TBL] [Abstract][Full Text] [Related]
6. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
Makiyama A; Sukawa Y; Kashiwada T; Kawada J; Hosokawa A; Horie Y; Tsuji A; Moriwaki T; Tanioka H; Shinozaki K; Uchino K; Yasui H; Tsukuda H; Nishikawa K; Ishida H; Yamanaka T; Yamazaki K; Hironaka S; Esaki T; Boku N; Hyodo I; Muro K
J Clin Oncol; 2020 Jun; 38(17):1919-1927. PubMed ID: 32208960
[TBL] [Abstract][Full Text] [Related]
9. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY; Oh DY; Yañez P; Bai Y; Ryu MH; Lee J; Rivera F; Alves GV; Garrido M; Shiu KK; Fernández MG; Li J; Lowery MA; Çil T; Cruz FM; Qin S; Luo S; Pan H; Wainberg ZA; Yin L; Bordia S; Bhagia P; Wyrwicz LS;
Lancet Oncol; 2023 Nov; 24(11):1181-1195. PubMed ID: 37875143
[TBL] [Abstract][Full Text] [Related]
11. Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.
Kim TH; Kim IH; Kang SJ; Choi M; Kim BH; Eom BW; Kim BJ; Min BH; Choi CI; Shin CM; Tae CH; Gong CS; Kim DJ; Cho AE; Gong EJ; Song GJ; Im HS; Ahn HS; Lim H; Kim HD; Kim JJ; Yu JI; Lee JW; Park JY; Kim JH; Song KD; Jung M; Jung MR; Son SY; Park SH; Kim SJ; Lee SH; Kim TY; Bae WK; Koom WS; Jee Y; Kim YM; Kwak Y; Park YS; Han HS; Nam SY; Kong SH;
J Gastric Cancer; 2023 Jan; 23(1):3-106. PubMed ID: 36750993
[TBL] [Abstract][Full Text] [Related]
12. An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts.
Li X; Zhai Z; Ding W; Chen L; Zhao Y; Xiong W; Zhang Y; Lin D; Chen Z; Wang W; Gao Y; Cai S; Yu J; Zhang X; Liu H; Li G; Chen T
Int J Surg; 2022 Sep; 105():106889. PubMed ID: 36084807
[TBL] [Abstract][Full Text] [Related]
13. Machine learning in clinical decision making.
Adlung L; Cohen Y; Mor U; Elinav E
Med; 2021 Jun; 2(6):642-665. PubMed ID: 35590138
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
